The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No. 150 and part review of technology appraisal No. 118): a systematic review and economic model

• M Hoyle,
• L Crathorne,
• J Peters,
• T Jones-Hughes,
• C Cooper,
• M Napier,
• P Tappenden,
• C Hyde

Affiliations

M Hoyle

Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK

L Crathorne

Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK

J Peters

Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK

T Jones-Hughes

Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK

C Cooper

Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK

M Napier

Royal Devon & Exeter Foundation Trust Hospital, Exeter, UK

P Tappenden

School of Health and Related Research (ScHARR), University of Sheffield, Sheffield, UK

C Hyde

Peninsula Technology Assessment Group (PenTAG), University of Exeter, Exeter, UK